EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Statera BioPharma's Enterprise Value is €0.00 Mil.
Statera BioPharma's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2022 was €-10.99 Mil. Therefore, Statera BioPharma's EV-to-FCF for today is 0.00.
The historical rank and industry rank for Statera BioPharma's EV-to-FCF or its related term are showing as below:
STU:7CB'
s EV-to-FCF Range Over the Past 10 Years
Min: -45.31 Med: -36.36 Max: -24.59
Current: -0.57
During the past 3 years, the highest EV-to-FCF of Statera BioPharma was -24.59. The lowest was -45.31. And the median was -36.36.
STU:7CB's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 16.26
vs STU:7CB: -0.57
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Statera BioPharma's PE Ratio (TTM) for today is calculated as:
Statera BioPharma's share price for today is €0.00.
Statera BioPharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Statera BioPharma EV-to-FCF Related Terms
Statera BioPharma EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Statera BioPharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Statera BioPharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Statera BioPharma EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Statera BioPharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Statera BioPharma's EV-to-FCF falls into.
Statera BioPharma's current Enterprise Value is €0.00 Mil.
Statera BioPharma's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-10.99 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Statera BioPharma (STU:7CB) has a EV-to-FCF of 0.00 as of Jul. 04, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Statera BioPharma and its competitors.
Is Statera BioPharma's EV-to-FCF too high?
Statera BioPharma's current EV-to-FCF is 0.00. Overall, Statera BioPharma has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Statera BioPharma's EV-to-FCF compare to NRBO and PALI?
Statera BioPharma's EV-to-FCF of 0.00 can be compared against companies in the Biotechnology industry. The industry median EV-to-FCF is 16.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.26, based on 332 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Statera BioPharma and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Statera BioPharma's current EV-to-FCF is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Statera BioPharma stock overvalued right now?
Statera BioPharma (STU:7CB) has a current EV-to-FCF of 0.00. The current EV-to-FCF is 0.00. Statera BioPharma's overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Statera BioPharma (STU:7CB), the current EV-to-FCF is 0.00 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:7CB has been successfully added to your 